Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 2,601–2,700 of 10,906
Reuter, N., Chen, X., Kropff, B., Peter, A. S., Britt, W. J., Mach, M., Überla, K., & Thomas, M. (2023) · Viruses · doi:10.3390/v15071500 · Cited by 30
Hitchings, M., Lewnard, J., Dean, N., Ko, A. I., Ranzani, O., Andrews, J. R., & Cummings, D. A. T. (2021) · medRxiv · doi:10.1097/ede.0000000000001484 · Cited by 31
Dhumal, S. B., Patil, A., More, A. N., Kamtalwar, S., Joshi, A. D., Gokarn, A. G., Mirgh, S. P., Thatikonda, P., Bhat, P., Murthy, V., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.037 · Cited by 27
Laing, E. D., Sterling, S. L., Richard, S. A., Epsi, N. J., Coggins, S. A., Samuels, E. C., Phogat, S., Yan, L., Moreno, N., Coles, C., et al. (2021) · medRxiv · doi:10.1101/2021.02.10.21251518 · Cited by 31
Gray, L. T., Raczy, M. M., Briquez, P. S., Marchell, T. M., Alpar, A. T., Wallace, R. P., Volpatti, L. R., Sasso, M. S., Cao, S., Nguyen, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121159 · Cited by 32
Schmidt, T., Klemis, V., Schub, D., et al. (2021) · medRxiv · doi:10.1101/2021.06.13.21258859 · Cited by 29
Cortés, A., Casado, J. L., Longo, F., Domingo, J. J. S., Saavedra, C., Velasco, H., Martín, A., Chamorro, J., Rosero, D. I., Fernández-Abad, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.017 · Cited by 30
Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Caliskan, G., Violán, C., Torán‐Monserrat, P., Vimercati, L., Tafuri, S., Boffetta, P., et al. (2023) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-023-00139-8 · Cited by 31
Predictors of mortality among long‐term care residents with SARS‐CoV ‐2 infection
Lee, D. S., Ma, S., Chu, A., Wang, C. X., Wang, X., Austin, P. C., McAlister, F. A., Kalmady, S. V., Kapral, M. K., Kaul, P., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17425 · Cited by 30
Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV
Griffin, D. W. J., Mangalore, R. P., Hoy, J., & McMahon, J. H. (2023) · AIDS · doi:10.1097/qad.0000000000003579 · Cited by 28
Botton, J., Dray‐Spira, R., Baricault, B., Drouin, J., Bertrand, M., Jabagi, M.-J., Weill, A., & Zureik, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.009 · Cited by 29
SARS-CoV-2 and male infertility: from short- to long-term impacts
Dai, P., Qiao, F., Chen, Y.-S. E., Chan, D. Y. L., Yim, H. C. H., Fok, K. L., & Chen, H. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02055-x · Cited by 31
Zhuang, X., Chen, L., Yang, S., Xia, S., Xu, Z., Zhang, T., Zeng, B., Yu, T., Yu, N., Wang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836274 · Cited by 27
Chen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 33
Aptamers in neuro-oncology: An emerging therapeutic modality
Doherty, C. L., Wilbanks, B. A., Khatua, S., & Maher, L. J., III (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad156 · Cited by 34
Scott, G. Y., Aborode, A. T., Adesola, R. O., Khan, M., Elebesunu, E. E., Adereti, A. O., Ahmad, M., Nibokun, E. O., Kwaku, S. D., Bakre, A. A., et al. (2025) · Outbreak Management and Response · doi:10.1080/29947677.2024.2443439 · Cited by 44
SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions
Timmers, L. F. S. M., Peixoto, J. V., Ducati, R. G., Bachega, J. F. R., Pereira, L. D. M., Caceres, R. A., Majolo, F., da Silva, G. L., Anton, D. B., Dellagostin, O. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91585-6 · Cited by 31
Vacunas frente a SARS-CoV-2 y piel
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.05.011 · Cited by 29
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B.-L., Whitener, B. M., VanBlargan, L., et al. (2021) · bioRxiv · doi:10.1101/2021.08.25.457693 · Cited by 45
Bettinger, J. A., Sadarangani, M., Serres, G. D., Valiquette, L., Vanderkooi, O. G., Kellner, J. D., Muller, M. P., Top, K. A., Isenor, J. E., McGeer, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051254 · Cited by 29
Sealy, R. E., & Hurwitz, J. L. (2021) · Microorganisms · doi:10.3390/microorganisms9081643 · Cited by 33
Urakawa, R., Isomura, E. T., Matsunaga, K., Kubota, K., & Ike, M. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07175-y · Cited by 32
COVID-19 vaccine-associated cerebral venous thrombosis in GermanyPreprint
Schulz, J. B., Berlit, P., Diener, H., Gerloff, C. P., Greinacher, A., Klein, C., Petzold, G. C., Piccininni, M., Poli, S., Röhrig, R., et al. (2021) · medRxiv · doi:10.1101/2021.04.30.21256383 · Cited by 29
Hafiz, I., Illian, D. N., Meila, O., Utomo, A. R. H., Susilowati, A., Susetya, I. E., Desrita, D., Siregar, G. A., & Basyuni, M. (2022) · Vaccines · doi:10.3390/vaccines10010082 · Cited by 33
Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)
Baghban, R., Ghasemian, A., & Mahmoodi, S. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03480-5 · Cited by 37
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Sellner, J., & Rommer, P. S. (2021) · Vaccines · doi:10.3390/vaccines9020099 · Cited by 29
Current RNA strategies in treating cardiovascular diseases
Chia, S. P. S., Pang, J. K. S., & Soh, B.-S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.028 · Cited by 34
Goffe, L., Antonopoulou, V., Meyer, C., Graham, F., Tang, M. Y., Lecouturier, J., Grimani, A., Bambra, C. L., Kelly, M. P., & Sniehotta, F. F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002084 · Cited by 31
Küçüksayan, E., Bozkurt, F., Yılmaz, M. T., Sırcan-Küçüksayan, A., Hanikoglu, A., & Özben, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-92447-x · Cited by 30
Berry, S. D., Goldfeld, K. S., McConeghy, K. W., Gifford, D. R., Davidson, H. E., Han, L., Syme, M. L., Gandhi, A. D., Mitchell, S. L., Harrison, J., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.8067 · Cited by 28
Zheng, B., Wang, L., Yi, Y., Yin, J., & Liang, A. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100943 · Cited by 57
Hertel, M., Schmidt‐Westhausen, A. M., Wendy, S., Heiland, M., Nahles, S., Preißner, R., & Preißner, S. (2022) · Vaccines · doi:10.3390/vaccines10030480 · Cited by 31
Structure and design of Langya virus glycoprotein antigens
Wang, Z., McCallum, M., Yan, L., Gibson, C. A., Sharkey, W., Park, Y.-J., Dang, H. V., Amaya, M., Person, A., Broder, C. C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314990121 · Cited by 32
Melo, A. R. D. S., de Macêdo, L. S., Invenção, M. D. C. V., de Moura, I. A., da Gama, M. A. T. M., de Melo, C. M. L., Silva, A. J. D., Batista, M. V. D. A., & de Freitas, A. C. (2022) · Genes · doi:10.3390/genes13122287 · Cited by 37
Yue, L., Zhou, J., Zhou, Y., Yang, X., Xie, T., Yang, M., Zhao, H., Zhao, Y., Yang, T., Li, H., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1996210 · Cited by 31
Nayyerabadi, M., Fourcade, L., Joshi, S. A., Chandrasekaran, P., Chakravarti, A., Massé, C., Paul, M.-L., Houle, J., Boubekeur, A. M., DuSablon, C., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.006 · Cited by 38
Early COVID-19 Vaccination of Romanian Medical and Social Personnel
Manolescu, L. S. C., ZAHARIA, C. N., Dumitrescu, A. I., Prasacu, I., Radu, M. C., Boeru, C., Boidache, L., Niță, I., Necsulescu, A., & Chivu, R. D. (2021) · Vaccines · doi:10.3390/vaccines9101127 · Cited by 28
Kolahchi, Z., Khanmirzaei, M., & Mowla, A. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120327 · Cited by 38
Shi, R., Zeng, J., Xu, L., Wang, F., Duan, X., Wang, Y., Wu, Z., Yu, D., Huang, Q., Yao, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104297 · Cited by 29
Trends in Clinical Presentation, Management, and Outcomes of STEMI in Patients With COVID-19
García, S., Dehghani, P., Stanberry, L. I., Grines, C. L., Patel, R. A. G., Nayak, K. R., Singh, A., Htun, W. W., Kabour, A., Ghasemzadeh, N., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.345 · Cited by 29
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesPreprint
Branche, A. R., Rouphael, N., Diemert, D. J., Falsey, A. R., Losada, C., Baden, L. R., Frey, S. E., Whitaker, J. A., Little, S. J., Anderson, E. J., et al. (2022) · medRxiv · doi:10.1101/2022.07.12.22277336 · Cited by 31
Self-citationImmune Cells, Gut Microbiota, and Vaccines: A Gender Perspective
Rio, P., Caldarelli, M., Chiantore, M., Ocarino, F., Candelli, M., Gasbarrini, A., Gambassi, G., & Cianci, R. (2024) · Cells · doi:10.3390/cells13060526 · Cited by 34
Tcheou, J., Raskin, A. J., Singh, G., Kawabata, H., Bielak, D. A., Sun, W., González‐Domínguez, I., Sather, D. N., García‐Sastre, A., Palese, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791764 · Cited by 28
COVID-19 vaccine trials: The use of active controls and non-inferiority studies
Fleming, T. R., Krause, P. R., Nason, M., Longini, I. M., & Restrepo, A. M. H. (2021) · Clinical Trials · doi:10.1177/1740774520988244 · Cited by 28
Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery
Sunoqrot, S., Gaber, S. A. A., Abujaber, R., Al-Majawleh, M., & Talhouni, S. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00843 · Cited by 35
Expectations and Prior Experiences Associated With Adverse Effects of COVID-19 Vaccination
Schäfer, I., Oltrogge, J. H., Nestoriuc, Y., Warren, C. V., Brassen, S., Blattner, M., Lühmann, D., Tinnermann, A., Scherer, M., & Büchel, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4732 · Cited by 33
Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice
Çimen, İ., Natarelli, L., Kichi, Z. A., Henderson, J. M., Farina, F. M., Briem, E., Aslani, M., Megens, R. T. A., Jansen, Y. J. F. M., Mann-Fallenbuchel, E., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf3357 · Cited by 32
Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada
Papst, I., Li, M., Champredon, D., Bolker, B. M., Dushoff, J. G., & Earn, D. J. D. (2021) · BMC Public Health · doi:10.1186/s12889-021-10611-4 · Cited by 30
Iqbal, S. M., Rosen, A. M., Edwards, D. K., Bolio, A., Larson, H. J., Servin, M., Rudowitz, M., Carfí, A., & Ceddia, F. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1429265 · Cited by 31
Zhang, C., Teng, Y., Bai, X., Tang, M., Stewart, W., Chen, J., Xu, X., & Zhang, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c13404 · Cited by 37
Neuromuscular complications of coronavirus disease-19
Suh, J., & Amato, A. A. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000970 · Cited by 33
North, C. M., Barczak, A. K., Goldstein, R. H., Healy, B. C., Finkelstein, D. M., Ding, D. D., Kim, A., Boucau, J., Shaw, B. M., Gilbert, R. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab643 · Cited by 29
Self-citationRNA Viruses, Pandemics and Anticipatory Preparedness
García-Blanco, M. A., Ooi, E. E., & Sessions, O. M. (2022) · Viruses · doi:10.3390/v14102176 · Cited by 28
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
Zasada, A. A., Darlińska, A., Wiatrzyk, A., Woźnica, K., Formińska, K., Czajka, U., Główka, M., Lis, K., & Górska, P. (2023) · Viruses · doi:10.3390/v15091786 · Cited by 39
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
Wang, Z., Jacobus, E. J., Stirling, D. C., Krumm, S. A., Flight, K. E., Cunliffe, R. F., Mottl, J., Singh, C., Mosscrop, L. G., Santiago, L. A., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102045 · Cited by 31
Liu, Z., Wu, H., Egland, K. A., Gilliland, T. C., Dunn, M. D., Luke, T. C., Sullivan, E. J., Klimstra, W. B., Bausch, C. L., & Whelan, S. P. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940652 · Cited by 26
Bouwmans, P., Messchendorp, A. L., Sanders, J., Hilbrands, L. B., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., ten Dam, M. A., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02680-3 · Cited by 27
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV
Matveev, V., Mihelic, E. Z., Benko, E., Budylowski, P., Grocott, S., Lee, T., Korosec, C. S., Colwill, K., Stephenson, H., Law, R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107915 · Cited by 28
Strategies for Vaccine Prioritization and Mass Dispensing
Lee, E. K., Li, Z. L., Liu, Y. K., & LeDuc, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050506 · Cited by 32
Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models
Sheward, D. J., Mandolesi, M., Urgard, E., Kim, C., Hanke, L., Vidakovics, L. P., Pankow, A. P., Smith, N. L., Dopico, X. C., McInerney, G. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100450 · Cited by 30
Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad017 · Cited by 28
Waddington, S. N., Peranteau, W. H., Rahim, A. A., Boyle, A. K., Kurian, M. A., Gissen, P., Chan, J. K. Y., & David, A. L. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12659 · Cited by 31
Hannauer, F., Black, R., Ray, A. D., Stulz, E., Langley, G. J., & Holman, S. W. (2023) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9596 · Cited by 35
Allen, N., Brady, M., Riain, U. N., Conlon, N. P., Domegan, L. M., Martín, A. I. C., Walsh, C., Doherty, L., Higgins, E., Kerr, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.758118 · Cited by 33
Takeuchi, Y., Iwagami, M., Ono, S., Michihata, N., Uemura, K., & Yasunaga, H. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.088 · Cited by 30
LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment
Xue, Y., Hou, X., Zhong, Y., Zhang, Y., Du, S., Kang, D. D., Wang, L., Wang, C., Li, H., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57149-2 · Cited by 36
Bruminhent, J., Setthaudom, C., Chaumdee, P., Boongird, S., Kiertiburanakul, S., Malathum, K., Nongnuch, A., Phuphuakrat, A., Jirasiritham, S., Janphram, C., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16867 · Cited by 30
Vandergaast, R., Carey, T. S., Reiter, S., Lathrum, C., Lech, P. J., Gnanadurai, C. W., Haselton, M., Buehler, J., Narjari, R., Schnebeck, L., et al. (2021) · mSphere · doi:10.1128/msphere.00170-21 · Cited by 27
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer
Cai, J., Liu, Z., Chen, S., Zhang, J., Li, H., Wang, X., Feng, Y., Wang, S., Li, X., Li, Y., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00625-8 · Cited by 41
“The approval of two messenger RNA (mRNA)-based COVID-19 vaccines have underscored the remarkable potential of RNA-based therapeutics [1–3].”
Verma, A. K., Kumar, I., Singh, P. K., Ansari, M. S., Singh, H. A., Sonkar, S., Prakash, A., Ojha, R., & Shukla, R. C. (2022) · European Radiology · doi:10.1007/s00330-021-08475-8 · Cited by 31
Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
Lopera, T. J., Chvatal‐Medina, M., Flórez‐Álvarez, L., Zapata-Cardona, M. I., Taborda, N. A., Rugeles, M. T., & Hernández, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879036 · Cited by 33
Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response
Mohan, A., Iyer, V. A., Kumar, D., Batra, L., & Dahiya, P. (2023) · Life · doi:10.3390/life13112121 · Cited by 59
Grant, M. D., Bentley, K., Fielding, C. A., Hatfield, K. M., Ings, D. P., Harnum, D. O. A., Wang, E. C. Y., Stanton, R. J., & Holder, K. A. (2023) · JCI Insight · doi:10.1172/jci.insight.170681 · Cited by 31
Nucleoside‐modified messenger RNA COVID‐19 vaccine platform
Roncati, L., & Corsi, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26924 · Cited by 28
Bianchi, F. P., Stefanizzi, P., Martinelli, A., Brescia, N., & Tafuri, S. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.036 · Cited by 29
Cheng, X., Liu, S., Sun, J., Liu, L., Ma, X., Li, J., Fan, B., Chen, Y., Zhao, Y., Liu, S., et al. (2023) · Advanced Materials · doi:10.1002/adma.202310886 · Cited by 32
Nojszewska, M., Kalinowska, A., Adamczyk-Sowa, M. H., Kułakowska, A., & Bartosik-Psujek, H. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0016 · Cited by 32
Karbiener, M., Farcet, M. R., Schwaiger, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab482 · Cited by 28
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
Terpos, E., Karalis, V. D., Ntanasis‐Stathopoulos, I., Evangelakou, Z., Gavriatopoulou, M., Manola, M. S., Malandrakis, P., Gianniou, D. D., Kastritis, E., Trougakos, I. P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020338 · Cited by 29
Chen, D., Liu, Z., Guo, L., Yang, L., Zhao, Y., & Yang, M. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.159318 · Cited by 32
Vaccinations, Mobility and COVID-19 Transmission
Guo, J., Deng, C. R., & Гу, Ф. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010097 · Cited by 32
French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge
Lacroix, C., Salvo, F., Gras‐Champel, V., et al. (2021) · Therapies · doi:10.1016/j.therap.2021.05.003 · Cited by 28
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data
Epstein, S., Xia, Z., Lee, A., Dahl, M., Edwards, K. R., Levit, E., Longbrake, E. E., Perrone, C. M., Kavak, K. S., Weinstock‐Guttman, B., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103433 · Cited by 28
Zivkovic, S. A., Gruener, G., & Narayanaswami, P. (2021) · Muscle & Nerve · doi:10.1002/mus.27179 · Cited by 27
Cordtz, R., Kristensen, S., Westermann, R., Duch, K. S., Pearce, F., Lindhardsen, J., Torp-Pedersen, C. T., Andersen, M. P., & Dreyer, L. (2022) · Rheumatology · doi:10.1093/rheumatology/keac241 · Cited by 29
Suhandynata, R. T., Bevins, N., Tran, J. T., Huang, D., Hoffman, M. A., Lund, K., Kelner, M. J., McLawhon, R. W., Gonias, S. L., Nemazee, D. A., et al. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab080 · Cited by 30
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 37
Nejad, M.-M. M., Shobeiri, P., Dehghanbanadaki, H., Tabary, M., Aryannejad, A., Ghadery, A. H., Shabani, M., Moosaie, F., SeyedAlinaghi, S., & Rezaei, N. (2022) · Virology Journal · doi:10.1186/s12985-022-01858-3 · Cited by 30
COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
Marsh, E. B., Kornberg, M. D., Kessler, K., Haq, I. U., Patel, A. D., Nath, A., Schierman, B., & Jones, L. K. (2021) · Neurology · doi:10.1212/wnl.0000000000012578 · Cited by 33
Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review
Wollina, U., Chiriac, A. E., Kocić, H., Koch, A., & Brzeziński, P. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-021-00876-0 · Cited by 31
Raethke, M., van Hunsel, F. P. A. M., Thurin, N. H., Dureau‐Pournin, C., Mentzer, D., Kovačić, B., Skvrce, N. M., Clercq, E. D., Sabbe, M., Trifirò, G., et al. (2023) · Drug Safety · doi:10.1007/s40264-023-01281-9 · Cited by 28
Legumain In Situ Engineering Promotes Efferocytosis of CAR Macrophage to Treat Cardiac Fibrosis
Liu, Z., Chen, C., Zhang, Y., Ji, F., Liu, H., Du, H., Guo, Y., Dong, X., Yang, Z., Han, M., et al. (2025) · Advanced Materials · doi:10.1002/adma.202417831 · Cited by 31
Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist
Andrew, M. K., Schmader, K. E., Rockwood, K. J., Clarke, B., & McElhaney, J. E. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s295522 · Cited by 30
Chambers, C., Soo, G. L., Engel, A. L., Glass, I. A., Frassetto, A., Martini, P. G. V., & Cherry, T. J. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.7.7 · Cited by 38
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.